Dr Liz Dallimore on the exciting times ahead for Argenica Therapeutics as they fast track Phase 2
MAKING MONEY MATTER: Biotech companies have not been top of investors minds recently but I was excited to speak with Dr Liz Dallimore of Argenica Therapeutics (ASX:AGN) who are moving from Phase 1 to Phase 2 trials. Since we last spoke there has been a steady increase in the share price as they work on a drug to reduce brain damage after strokes as well as other brain injuries.TIME STAMPS:00:00 intro02:00 Background to Argenica Therapeutics (asx:AGN) and what sets them apart04:30 Phase 1 and Phase 2 trials and the outcomes from the trials06:50 The competition08:30 The recent placement and use of funds going forward12:00 The importance of the FDA approval and the market in the USA14:30 Timelines for the phase 2 trials and any challenges?18:00 Progress with the FDA21:00 Current valuation and milestones ahead and future partners23:30 The other applications for the company going forward26:30 Three reasons to sit up and take notice right now
- Forums
- ASX - By Stock
- AGN Media thread
Dr Liz Dallimore on the exciting times ahead for Argenica...
-
-
- There are more pages in this discussion • 95 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AGN (ASX) to my watchlist
|
|||||
Last
79.0¢ |
Change
0.010(1.28%) |
Mkt cap ! $100.4M |
Open | High | Low | Value | Volume |
78.0¢ | 80.5¢ | 78.0¢ | $71.40K | 90.43K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 15000 | 78.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
80.5¢ | 2444 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 15000 | 0.785 |
1 | 10000 | 0.780 |
2 | 25477 | 0.775 |
2 | 16000 | 0.770 |
2 | 58000 | 0.760 |
Price($) | Vol. | No. |
---|---|---|
0.805 | 2444 | 1 |
0.830 | 2298 | 2 |
0.850 | 10650 | 2 |
0.860 | 12500 | 1 |
0.865 | 14194 | 2 |
Last trade - 15.55pm 23/08/2024 (20 minute delay) ? |
AGN (ASX) Chart |
The Watchlist
SER
STRATEGIC ENERGY RESOURCES LIMITED
David DeTata, Managing Director
David DeTata
Managing Director
SPONSORED BY The Market Online